Application

We are pleased to announce that the NINDS Clinical Trials Methodology Course (CTMC) is accepting applications for the 2019 cohort. The overarching goal of the CTMC is to help investigators develop scientifically rigorous, yet practical clinical trial protocols. Our focus is on investigators who have not previously designed their own prospective, interventional clinical trials. 

Informational Webinar (slides and video):

Need more information about the CTMC? Review this slide set presented at a recent CTMC informational webinar. The video of the webinar is below.

 
Course:

There is a combination of distance learning activities and a REQUIRED residential course, along with small group mentorship from experienced clinical trialists and biostatisticians. The residential part of the course will be held July 22 – 25, 2019 in Iowa City, IA. Funding for travel (within the US) and accommodations will be provided for participants.

Who Should Apply?

Qualified applicants from clinical disciplines focused on neurological disease or injury, along with biostatisticians working on projects with clinical neuroscience researchers should apply. All preliminary trial ideas are encouraged, but it is REQUIRED that protocols be focused on the clinical neurosciences. Trainees should have content area mentors to assist them with the science and implementation of their project. A small number of projects may qualify for additional work using clinical trial simulation.

Application:

The FINAL application is here

DEADLINE:

The application submission deadline is February 28, 2019 at midnight. Application forms and additional details are available on the course website: http://neurotrials.training. Early applications may be considered for early acceptance.

Have Questions?

Please contact NINDS‐CTMC‐Info@umich.edu or William Meurer, MD, MS with any questions.

Thank you.

The NINDS Clinical Trials Methodology Course is supported by the NIH‐NINDS grant R25 NS088248 and is administered by the University of Michigan, the University of Iowa, and Los Angeles BioMed. Additional support is provided by the American Academy of Neurology.